C&EN White Paper
Producing therapeutic peptides using biotechnology
Brought to you by Olon S.P.A- Olon

Synthesis of Therapeutic Peptides via Microbial Fermentation with Recombinant DNA-Technology Scenario, Challenges, Olon expertise

Key Objectives:

Biotechnology represents a unique opportunity to improve industrial process sustainability
  • LIMITED USE OF SOLVENTS → Low environmental impact
  • COST EFFECTIVE APPROACH → Recombinant approach is the unique SUSTAINABLE and COST COMPETITIVE process

Olon is developing a strong know-how for development of rDNA peptides and proteins.

Brought to you by:
Olon S.P.A- Olon
This content was created by Olon, without editorial input from the C&EN Media Group. For more information on C&EN’s custom products, visit our C&EN Media Kit .
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy